SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 18, 2003
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-31979 | 84-1460811 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
3200 Walnut Street, Boulder, Colorado 80301
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (303) 381-6600
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
On December 18, 2003, the Registrant issued a press release announcing a licensing and collaboration agreement between the Registrant and AstraZeneca PLC and a conference call to be held by the Registrant on December 19, 2003 to discuss the announcement. The full text of the press release is attached hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARRAY BIOPHARMA INC. |
||||
Date: December 18, 2003 |
By: |
/s/ ROBERT E. CONWAY Robert E. Conway Chief Executive Officer |
||
| Exhibit No. |
|
|
|---|---|---|
| 99.1 | Press release dated December 18, 2003 entitled "Array BioPharma and AstraZeneca Announce Oncology Collaboration" |